Angiodynamics Inc. (ANGO)
Should You Buy AngioDynamics (ANGO) After Golden Cross?
From a technical perspective, AngioDynamics, Inc. (ANGO) is looking like an interesting pick, as it just reached a key level of support. ANGO's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Wall Street Analysts Predict a 74.25% Upside in AngioDynamics (ANGO): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 74.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for July 29th
KRO, FUNC, PRG, ANGO and HGTY have been added to the Zacks Rank #1 (Strong Buy) List on July 29, 2024.
AngioDynamics: Lumpy Progress Is Still Progress
AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife generated double-digit year-over-year growth, while AlphaVac bounced back strongly on a sequential basis, and gross margin improved more than three points. Execution remains the key here, as Auryon, AlphaVac, and NanoKnife all have legitimate growth potential, but significant competition as well.
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to earnings of $0.02 per share a year ago.
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
